Nilotinib

4-methyl- N-[3 - (4- methylimidazol -1-yl ) -5 - ( trifluoromethyl) phenyl] -3 - [(4- pyridin-3- ylpyrimidin -2-yl ) amino] benzamide ( IUPAC)

L01XE08

Tyrosine kinase inhibitor

Template: Infobox chemical / molecular formula search available

Nilotinib (trade name: Tasigna ®, manufactured by Novartis) was developed under the name of AMN107 and is a specific BCR -ABL tyrosine kinase inhibitor. Tasigna was the first time in mid-2007 in Switzerland for the treatment of chronic myeloid leukemia ( CML), a short time later, the approval was granted in the U.S. and the EU. Since 1 January 2008, the prescription drug in Germany for the treatment of CML is available.

The approval was initially for patients who can not tolerate treatment with imatinib or fail to respond. The end of 2010 was followed by the approval for newly diagnosed patients. The reasons for approval were large phase III treatment studies in which nilotinib was also shown in imatinib-resistant CML patients effectiveness.